- About us
- Clinical trials
- News & Publications
SOTIO participated at the BIO International Convention 2013
SOTIO successfully participated at the BIO International Convention 2013 (from April 22 to 25, 2013), an annual gathering of biotech industry leaders. This year’s convention held at McCormic Place in Chicago (US), with thousands of participants from pharmaceutical companies, biotechnology firms, university researchers etc.
SOTIO receives EMA approval
SOTIO receives European Medicines Agency approval to initiate Phase III VIABLE Clinical Trial of DCVAC/PCa, an active cellular immunotherapy drug targeted for prostate cancer patients. Lead Candidate from SOTIO’s DCVAC program.
SOTIO a.s. appoints Chiltern International
SOTIO a.s. has selected Chiltern International Limited to be the Contract Research Organization (CRO) that carries out the European part of its phase III global clinical trial entitled VIABLE, which will include 1,170 prostate cancer patients from Europe and the U.S.